LumiraDx

LumiraDx is a next-generation point of care diagnostics company that was founded in 2014. The company's slogan is "Transforming community-based healthcare through POC diagnostics & making lab-comparable tests accessible to all." LumiraDx aims to make efficient and accurate diagnostic tests available at the point of care. Their innovative diagnostic platform supports a broad menu of tests with lab comparable performance, covering infectious diseases, cardiovascular disease, diabetes, and coagulation disorders. As of 14th February 2023, LumiraDx received Post-IPO Equity investment from Morningside Venture Investments. The company's headquarters is in the United Kingdom. LumiraDx's diagnostic testing solutions have gained significant attention, being deployed across various settings including laboratories, urgent care, physician offices, pharmacies, schools, and workplaces, enabling screening, diagnosis, and wellness monitoring. Additionally, the company has developed a comprehensive portfolio of fast, accurate, and cost-efficient COVID-19 testing solutions, from the lab to the point of need. Overall, LumiraDx's commitment to transforming community healthcare through innovative diagnostics, along with a strategic equity investment from Morningside Venture Investments, positions the company as a major player in the healthcare and medical devices industry.